FDA Approves Navepegritide: First Once-Weekly Achondroplasia Therapy

The Food and Drug Administration has approved a once-weekly therapy, navepegritide (Yuviwel, Ascendis Pharma), to increase growth in children aged 2 years and older living with achondroplasia, the most common form of dwarfism. The approval, announced March 2, 2026, marks the first once-weekly treatment option for this condition, offering a novel approach to managing growth challenges associated with achondroplasia. The medication is anticipated to be available in the U.S. During the second quarter of 2026.

Understanding Achondroplasia and Navepegritide’s Mechanism

Achondroplasia is a genetic disorder affecting bone and cartilage development, resulting in disproportionately short stature. It’s caused by mutations in the FGFR3 gene, leading to overactive signaling that inhibits bone growth. Navepegritide is a prodrug of C-type natriuretic peptide (CNP), designed to counteract this overactive signaling. By providing continuous exposure to active CNP, the medication aims to promote bone growth and improve height velocity in children with open epiphyses – the growth plates at the ends of long bones.

Clinical Trial Data Supporting the Approval

The FDA’s approval is based on data from three randomized, double-blind, placebo-controlled trials, along with three years of open-label extension data. A phase 2b trial, previously reported by Healio, demonstrated a statistically significant increase in annualized growth velocity in children and adolescents receiving navepegritide. Participants receiving the medication experienced a mean annualized growth velocity of 5.89 cm per year, compared to 4.41 cm per year in the placebo group (P < .001). The treatment also led to greater increases in height z scores, both achondroplasia-specific and CDC-based, from baseline to one year compared with placebo. Importantly, no children discontinued the trial due to adverse events.

These findings suggest that navepegritide has the potential to significantly impact the physical development of children with achondroplasia. Though, it’s crucial to remember that clinical trials are conducted under carefully controlled conditions and real-world outcomes may vary. The long-term effects of the medication are still being studied through ongoing extension trials.

Expert Perspective and Considerations

“The approval of once-weekly Yuviwel is a major step forward in the treatment of children with achondroplasia, giving physicians for the first time the option of prescribing a once-weekly medicine backed by compelling efficacy and excellent tolerability data from three randomized, double-blind, placebo-controlled clinical trials,” said Carlos A. Bacino, MD, FACMG, professor of molecular and human genetics at Baylor College of Medicine and Texas Children’s Hospital, in a press release. He emphasized the importance of individualized care plans, incorporating Yuviwel into discussions with patients and families to address their specific needs and goals.

It’s important to note that Healio was unable to confirm Dr. Bacino’s relevant financial disclosures prior to publication. Transparency regarding potential conflicts of interest is a cornerstone of responsible medical reporting.

Accelerated Approval and Future Monitoring

Navepegritide was approved under the FDA’s accelerated approval program. This pathway allows for the approval of medications addressing serious conditions with unmet medical needs based on surrogate endpoints – measures that are reasonably likely to predict clinical benefit. In this case, increased growth velocity is considered a surrogate endpoint. Continued approval is contingent upon verification of clinical benefit in confirmatory trials. In other words Ascendis Pharma will require to conduct further studies to demonstrate that the increased growth velocity translates into meaningful improvements in long-term health outcomes for children with achondroplasia.

The FDA also granted a rare pediatric disease priority review voucher with the approval. This voucher can be used to expedite the review of a subsequent drug application, incentivizing pharmaceutical companies to invest in the development of treatments for rare pediatric diseases. More information about the priority review voucher program is available on the FDA website.

Broader Context: Ongoing Research and Support for Achondroplasia

Achondroplasia affects an estimated 1 in 15,000 to 40,000 live births. While there is no cure, management focuses on addressing the medical complications associated with the condition, such as spinal stenosis, hydrocephalus, and ear infections. Beyond medical interventions, support groups and advocacy organizations play a vital role in providing resources and community for individuals and families affected by achondroplasia. Little People of America is one such organization, offering information, support, and advocacy for people with dwarfism and their families.

What’s Next: Confirmatory Trials and Long-Term Data

The approval of navepegritide represents a significant advancement, but ongoing research is crucial. Ascendis Pharma is committed to conducting confirmatory trials to solidify the long-term benefits of the medication. These trials will assess not only continued growth velocity but also the impact on other aspects of health, such as quality of life and the development of complications associated with achondroplasia. The FDA will closely monitor the results of these trials as part of the accelerated approval process. Continued surveillance and data collection will be essential to understand the medication’s long-term safety profile and identify any potential rare adverse effects.